Panel Discussion: An Overview of the Hippo Pathway Drug Development Landscape

Time: 9:00 am
day: Conference Day One


  • What indications are showing most promise for therapeutic intervention on the Hippo pathway?
  • Will targeted approaches on TEAD isoforms be the key to navigating risk of toxicity from pan-TEADs?
  • How do we convince investors Hippo pathway treatments are worth their time when some consider the pathway ‘unvalidated’?
  • What are the advantages/risks in targeting YAP/TAZ and TEAD interactions?